2023 World Conference on Lung Cancer (Posters)-EP11.01. Neutrophil to Lymphocite Ratio in Patients Treated with Immunotherapy after Progression on Chemotherapy

EP11.01. Neutrophil to Lymphocite Ratio in Patients Treated with Immunotherapy after Progression on Chemotherapy - PDF(Slides)

Back to course

Pdf Summary

This study aimed to investigate the association between indicators of systemic inflammation and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) who received nivolumab treatment. The researchers conducted a retrospective cohort study of 105 patients with metastatic or recurrent NSCLC who were treated with nivolumab as a second-line or further-line therapy. The patients' pre-treatment neutrophil-to-lymphocyte ratio (NLR) was calculated, and they were categorized into two sub-groups based on the magnitude of their NLR values.<br /><br />The results showed that high NLR levels were associated with poor overall survival, but not with progression-free survival (PFS). The median overall survival for patients with low NLR was 18.2 months, compared to 10.1 months for patients with high NLR. However, the difference in PFS between the two groups was not statistically significant.<br /><br />The study had some limitations, such as a small sample size and a retrospective design. However, the findings provide real-life data on the association between NLR and survival outcomes in NSCLC patients receiving nivolumab treatment.<br /><br />In conclusion, this study suggests that high neutrophil-to-lymphocyte ratio is associated with poor overall survival in pre-treated NSCLC patients who received nivolumab treatment. These findings highlight the potential of inflammation markers, such as NLR, as prognostic factors for NSCLC patients receiving immunotherapy. Further studies with larger sample sizes are needed to confirm these findings and explore the underlying mechanisms.

Asset Subtitle

Marko Jakopovic

Meta Tag

Speaker Marko Jakopovic

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

systemic inflammation

overall survival

non-small cell lung cancer

NSCLC

nivolumab treatment

neutrophil-to-lymphocyte ratio

progression-free survival

real-life data

prognostic factors

immunotherapy